<DOC>
	<DOCNO>NCT01119118</DOCNO>
	<brief_summary>The purpose research study assess effect ZD4054 prostate cancer spread bone use new image technique . In particular , study use fluorodeoxyglucose ( FDG ) 18F-Sodium Fluoride ( NaF ) PET/computed tomography ( CT ) MRI scan look change bone metastasis ZD4054 therapy .</brief_summary>
	<brief_title>ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging ( PET/MRI ) Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Men &gt; 18 year age . 2 . Histologically proven adenocarcinoma prostate . 3 . Presence radiographic bone metastasis least one amenable serial image use MRI/PET imaging . 4 . Patients must evidence progressive disease either radiographic progression rise PSA within 4 week prior registration . 5 . Patients must prior treatment bilateral orchiectomy primary androgendeprivation therapy . 6 . For patient previously treat flutamide ( Eulexin ) , Nilutamide ( Nilandron ) , bicalutamide ( Casodex ) : Patients must discontinue flutamide &gt; 4 week prior registration continue evidence progressive disease . For bicalutamide nilutamide , patient must discontinue drug &gt; 6 week prior registration evidence progressive disease . 7 . Prior therapy permit long give &gt; 4 week prior registration , evidence disease progression meet . 8 . Patients must prior radiotherapy &lt; 4 week prior registration . 9 . Prior use bisphosphonates allow start least 12 week prior registration ( continue current dose/schedule study ) . 10 . Patient prior Strontium 89 , Samarium 153 , radioisotope . 11 . No concurrent use estrogen , estrogenlike agent 12 . Patients must adequate organ function 13 . ECOG performance status 02 . 1 . Use potent CYP450 inducer ( phenytoin , rifampicin , carbamazepine phenobarbitone , St. John 's Wort ) within 2 week prior start study treatment . 2 . Prior therapy endothelin receptor antagonist family history hypersensitivity endothelin antagonist . 3 . History past current epilepsy , epilepsy syndrome , seizure disorder . 4 . Stage II , III IV cardiac failure ( classify accord New York Heart Association ( NYHA ) classification ) , myocardial infarction within 6 month prior study entry , leave ventricular function ( LVEF ) institutional normal limit . 5 . QT interval correct heart rate ( Bazett 's correction ) ( QTcB ) &gt; 470 msec . 6 . Previous history presence another cancer , prostate cancer treat squamous/basal cell carcinoma skin , within last 5 year . 7 . Major surgery within 6 week registration . 8 . Hemoglobin ( Hb ) &lt; 9 g/dL . Concomitant use erythropoietin blood transfusion allow . 9 . Inability take absorb oral medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>castrate-resistant prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>